Short Interest in InterCure Ltd. (NASDAQ:INCR) Increases By 320.4%

InterCure Ltd. (NASDAQ:INCR) was the target of a large increase in short interest in February. As of February 27th, there was short interest totaling 20,573 shares, an increase of 320.4% from the February 12th total of 4,894 shares. Based on an average daily volume of 84,411 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company’s stock are short sold. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 84,411 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of InterCure in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

InterCure Stock Performance

Shares of INCR stock traded down $0.01 on Wednesday, reaching $0.81. The company had a trading volume of 26,080 shares, compared to its average volume of 63,046. The business’s 50-day moving average is $0.91 and its 200 day moving average is $1.25. InterCure has a one year low of $0.68 and a one year high of $1.77. The company has a quick ratio of 1.09, a current ratio of 1.85 and a debt-to-equity ratio of 0.27.

About InterCure

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.